Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Cash from Operations: 2016-2024

Historic Cash from Operations for Monopar Therapeutics (MNPR) over the last 9 years, with Dec 2024 value amounting to -$6.4 million.

  • Monopar Therapeutics' Cash from Operations fell 112.07% to -$1.3 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$4.1 million, marking a year-over-year decrease of 42.61%. This contributed to the annual value of -$6.4 million for FY2024, which is 18.50% up from last year.
  • According to the latest figures from FY2024, Monopar Therapeutics' Cash from Operations is -$6.4 million, which was up 18.50% from -$7.9 million recorded in FY2023.
  • Over the past 5 years, Monopar Therapeutics' Cash from Operations peaked at -$4.7 million during FY2020, and registered a low of -$7.9 million during FY2023.
  • In the last 3 years, Monopar Therapeutics' Cash from Operations had a median value of -$7.2 million in 2022 and averaged -$7.2 million.
  • In the last 5 years, Monopar Therapeutics' Cash from Operations slumped by 56.95% in 2021 and then rose by 18.50% in 2024.
  • Yearly analysis of 5 years shows Monopar Therapeutics' Cash from Operations stood at -$4.7 million in 2020, then crashed by 56.95% to -$7.3 million in 2021, then climbed by 1.21% to -$7.2 million in 2022, then dropped by 8.71% to -$7.9 million in 2023, then increased by 18.50% to -$6.4 million in 2024.